Biological evaluation of 2,3-dioxoindolin-N-phenylacetamide derivatives as potent CDC25B and PTP1B phosphatase inhibitors. Braz. J. Pharm. Sci. 2020;56:e00222. doi:10.1590/s2175-97902019000400222